Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF.

Molecular cancer research : MCR - 1 Mar 2016

Hechtman Jaclyn F, Zehir Ahmet, Yaeger Rona, Wang Lu, Middha Sumit, Zheng Tao, Hyman David M, Solit David, Arcila Maria E, Borsu Laetitia, Shia Jinru, Vakiani Efsevia, Saltz Leonard, Ladanyi Marc

Abstract excerpt

UNLABELLED: Targeted therapy for metastatic colorectal carcinoma consists of anti-EGFR therapy for patients with RAS/RAF wild-type tumors. However, the response rate remains low, suggesting the presence of alternative drivers possibly also representing potential therapeutic targets. We investigated receptor tyrosine kinase (RTK) alterations and MAP2K1 (MEK1) mutations in a large cohort of colorectal carcinoma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Amplification

Share to MAP Kinase Kinase 1

Share to raf Kinases

Share to ras Proteins

Share to Receptor Protein-Tyrosine Kinases

Share to Sequence Analysis, DNA

Source

Open in PubMed Open full text

Identifiers

PMID: 26660078
DOI: 10.1158/1541-7786.MCR-15-0392-T
PMCID: PMC4972456

Genes

EGFR
ERBB2
ETV6
GRB7
NCOA4
NTRK3
RET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF.PMID 26660078Read ↗

RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer.Semantic proximity Read ↗

NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability.Semantic proximity Read ↗

Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications.Semantic proximity Read ↗

Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases.Semantic proximity Read ↗

Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies.Semantic proximity Read ↗

Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial.Semantic proximity Read ↗

Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics.Semantic proximity Read ↗

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal CancerSemantic proximity Read ↗

Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience.Semantic proximity Read ↗

Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib.Semantic proximity Read ↗

Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase FusionsSemantic proximity Read ↗

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targetsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.